Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3053102 (Eli Lilly and Company)
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
LY3053102 is a humanized monoclonal antibody developed by Eli Lilly and Company for the treatment of muscle-wasting conditions, including sarcopenia and muscle atrophy. It functions as a neutralizing agent against myostatin (Growth Differentiation Factor 8, GDF-8), a member of the TGF-beta superfamily that acts as a potent negative regulator of skeletal muscle mass. By binding to and inhibiting myostatin, LY3053102 aims to promote muscle hypertrophy and improve physical function in populations experiencing significant muscle loss. The drug has been evaluated in Phase 1 clinical trials to determine its safety, tolerability, and pharmacokinetics in healthy subjects.
- Other names
- anti-myostatin/activin A antibodyanti-MSTN/Activin A mAb
02
Targets
GDF8 (Myostatin)
Beyond the preview
Go deeper on LY3053102 (Eli Lilly and Company).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3053102 (Eli Lilly and Company).